VanEck Israel ETFISRA

VanEck’s ISRA ETF is an Israeli equity wrapper that trades on Nasdaq with a mandate to track the performance of Israeli companies listed on major exchanges, with a focus on sectors like technology, healthcare, and financials. The fund’s expense ratio is 0.40%, a figure that sits at the heart of its business model-charging investors for the privilege of owning a basket of stocks they could assemble themselves. The Nasdaq listing confirms the ticker and provides basic market data, but the page offers no insight into the fund’s liquidity depth or tracking error. (source: Nasdaq, https://www.nasdaq.com/market-activity/etf/isra)

The fund’s SEC filing outlines the mandate and top holdings, confirming that ISRA’s portfolio is dominated by large-cap Israeli names like Teva Pharmaceuticals, Bank Hapoalim, and Bezeq. The filing does not, however, disclose liquidity metrics or how the fund might perform under geopolitical stress. The issuer’s marketing materials describe Israel’s innovation economy, but the fund’s holdings are a snapshot of its corporate establishment, not its startup scene. The disconnect between the thematic pitch and the actual basket is the fund’s most consistent feature. (source: SEC EDGAR fund search for ISRA, https://www.sec.gov/edgar/search/#/q=ISRA)

The VanEck ETF centre page confirms the fund’s identity, expense ratio, and top holdings, but the site offers no data on tracking error, liquidity, or how the fund’s holdings might respond to domestic policy shifts. The issuer’s materials sell a story of Israel’s tech ascendancy, yet the fund’s top 10 holdings include legacy financials and healthcare names, a fact that feels less like thematic alignment and more like index drift. The fee, meanwhile, is the only hard fact in the wrapper. (source: VanEck ETF centre, https://www.vaneck.com/)

The FINRA Fund Analyzer confirms the expense ratio of 0.40% but provides no further insight into the fund’s liquidity, tracking error, or how the basket might perform under stress. The tool’s output is a static confirmation of the fee and the fund’s existence, leaving investors to wonder whether the ETF’s liquidity is a feature or a fiction. The analyser’s data is useful for comparing fees, but it offers no comfort on execution quality or tracking precision. (source: FINRA Fund Analyzer, https://tools.finra.org/fund_analyzer/)

The Nasdaq listing for ISRA provides a price quote and volume data, but the page offers no insight into the fund’s liquidity depth or tracking error. The listing confirms the ticker’s existence on Nasdaq, but the data is thin, leaving investors to rely on the issuer’s marketing for thematic colour. The fund’s mandate is clear, but the mechanism for delivering it is opaque. (source: Nasdaq, https://www.nasdaq.com/market-activity/etf/isra)

What remains unproven is whether the fund’s liquidity is sufficient for large trades, how its holdings might perform under geopolitical stress, and whether the expense ratio of 0.40% is justified by tracking precision or thematic purity. The SEC filing confirms the mandate and top holdings, but the document is silent on liquidity metrics and tracking error. The issuer’s marketing sells a story, but the fund’s basket tells a different one. (source: SEC EDGAR fund search for ISRA, https://www.sec.gov/edgar/search/#/q=ISRA)

Deepening the file would require the issuer to disclose tracking error, liquidity depth, and how the fund’s holdings might respond to domestic policy shifts. The VanEck site and SEC filing confirm the fund’s identity and mandate, but they offer no insight into execution quality or thematic alignment. Until then, ISRA remains a wrapper with a fee, a ticker, and a thematic pitch that outshines its basket. (source: VanEck ETF centre, https://www.vaneck.com/)